header logo en


10 facts web

Cabozantinib, Crizotinib, Volitinib,

or Sunitinib in Treating Patients

With Locally Advanced or

Metastatic Papillary Kidney 

Cancer (S1500)

 Phase 2; 180 patients 
 Last updated: April 09, 2018
 STATUS: Recruiting (accepting new patients) (per ClinicalTrials.gov/NCT02761057)


is the trial for?

Patients with papillary kidney cancer (papillary renal cell carcinoma, RCC) who currently meet the following criteria:
  • histologically or cytologically confirmed papillary histology
  • metastatic or locally advanced disease
  • may have received prior surgery
  • has had no prior therapy OR may have received one prior systemic therapy for advanced or metastatic renal cell carcinoma provided that therapy was not sunitinib or pazopanib


is the key question that this trial is attempting to answer?

This phase 2 trial evaluates how various medications work in treating patients with papillary kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body.

The study investigates the comparative effectiveness of cabozantinib, crizotinib, volitinib, and sunitinib, specifically whether these medications can stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


patients might want to participate?

This clinical trial offers patients an opportunity to access a new therapy that may be effective for kidney cancer. This trial will further support the research in kidney cancer and potentially help other patients with kidney cancer. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.


will the trial be open?

The study is open (currently recruiting) – 180 patients worldwide are currently expected to participate.


is the trial available?

The trial will be available in 455 cancer centers worldwide.
For a complete list of trial locations, please click here:



What does the study look like?

Revision 02/19: This clinical trial is continuing to recruit papillary mRCC patients who will be randomized to receive either sunitinib or cabozantinib. 

There will be 4 study arms (groups): all participating patients will be randomly divided (by a computer) into one of four groups. Please note that patients in all groups will receive an active medication. No patient will receive a placebo.

Patients in group 1 will be assigned sunitinib (SutentTM), patients assigned group 2 will be treated with cabozantinib (CabometyxTM), both agents are approved for treatment of advanced RCC. Patients assigned group 3 will receive crizotinib (XalkoriTM), an agent approved for other types of cancer, but not for kidney cancer. Patients assigned to group 4 will be assigned volitinib (SavolitinibTM), an agent approved for other types of cancer, but not for kidney cancer.
  • sunitinib (Sutent™) is an oral, small-molecule, multi-targeted receptor tyrosine kinase inhibitor, already approved for the treatment of metastatic RCC
  • cabozantinib (CabometyxTM) is a tyrosine kinase inhibitor (targeted therapy), already approved for the treatment of metastatic RCC
  • crizotinib (XalkoriTM) is an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor (targeted therapy)
  • volitinib (SavolitinibTM) is an experimental small molecule inhibitor of c-Met

1) Sunitinib is taken by mouth once daily for 4 weeks then 2 weeks off.

2) Cabozantinib is taken by mouth once daily.

3) Crizotinib is taken by mouth twice daily.

4) Volitinib is taken by mouth once daily.


do I get more information?

Patient organisations supporting kidney cancer patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving kidney cancer patients. If there are no such organisations in your country, please email us for more information: This email address is being protected from spambots. You need JavaScript enabled to view it.


with other patients on this trial

If you want to connect with other patients considering or participating in this trial, you can find them here: List of organisations worldwide.


your experience 

If you would like to share your experience on this trial, send us an e-mail to: This email address is being protected from spambots. You need JavaScript enabled to view it.
Note that your experience would be helpful for other patients and patient organisations.


of the study

No results are available at this time. Future results will be linked here.
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.
Back to clinical trials overview: How can I find a clinical trial for my cancer?